FundedIQ
Biotechnology

Orthocell: Funding, Investors & Team (Sep 2026)

Orthocell is a regenerative medicine company dedicated to the development of breakthrough products to unlock the power of the human body to heal - restoring mobility, function and performance. Orthocell produces two complementary platform products – a collagen medical device and autologous cell therapies. CelGro™ platform of collagen medical devices are designed to augment surgical repair of bone, nerve, tendon and cartilage. The Company’s cell therapies include autologous tendon therapy and autologous chondrocyte implantation (OrthoACI™), which aim to regenerate damaged tendon and cartilage tissue.

orthocell.com LinkedIn Melville, Australia 11-50 employees
Biotechnology Medical Therapeutics B2C
Total raised
$11.2M
Rounds
1
Latest
Undisclosed round
Oct 2024

Orthocell has raised $11.2M across 1 funding round on record, the most recent an undisclosed round of $11.2M announced in Oct 2024.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Orthocell Company Profile and Key Stats

Total funding raised
$11.2M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$11.2M in Oct 2024
Employees
11-50
reported band
Headquarters
Melville, Australia

Latest funding round on record: Oct 2024.

Orthocell Funding Rounds

Date
Round
Amount
Undisclosed round
$11.2M

Orthocell Founders and Leadership Team

Name
Role
Contact
Ming Hao Zheng
Founder
Locked

Contact details for the Orthocell team: 1 of 1 has an email address on file.

Start 14-day free trial →

Orthocell Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
1,156
$4.0M

Orthocell's latest round of $11.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Orthocell in Biotechnology and Melville

Companies Similar to Orthocell

AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…

Series D $315M

The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…

Seed $2.0M

Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…

Undisclosed round $50.0M

Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…

Undisclosed round $3.5M

Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…

Undisclosed round $990k

Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…

Undisclosed round $10.1M

Imugene is a publicly-listed biotechnology company with operations in America and Europe,

Undisclosed round $8.6M

BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology

Undisclosed round $10.8M

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…

Undisclosed round $600M

Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…

Series A $13.3M

HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…

Undisclosed round $1.4M

Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…

Undisclosed round $320k

Orthocell Funding FAQs

What does Orthocell do?

Orthocell is a regenerative medicine company dedicated to the development of breakthrough products to unlock the power of the human body to heal - restoring mobility, function and performance. Orthocell produces two complementary platform products – a collagen medical device and autologous cell therapies. CelGro™ platform of collagen medical devices are designed to augment surgical repair of bone, nerve, tendon and cartilage. The Company’s cell therapies include autologous tendon therapy and autologous chondrocyte implantation (OrthoACI™), which aim to regenerate damaged tendon and cartilage tissue.

How much funding has Orthocell raised?

Orthocell has raised $11.2M across 1 round on record. The most recent is an undisclosed round of $11.2M announced in Oct 2024.

When did Orthocell last raise funding?

Orthocell's most recent funding round on record is an undisclosed round of $11.2M, announced in Oct 2024.

Who founded Orthocell?

FundedIQ lists Ming Hao Zheng (Founder) at Orthocell.

Where is Orthocell headquartered?

Orthocell is based in Melville, Western Australia, Australia.

How many employees does Orthocell have?

Orthocell is in the 11-50 employee band.

How does Orthocell's funding compare to other Biotechnology startups?

Orthocell's latest round of $11.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's Orthocell Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Orthocell is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.